Bolt Biotherapeutics
900 Chesapeake Drive
Redwood City
CA
94063
United States
Tel: (650) 665-9295
Website: https://www.boltbio.com/
Email: careers@boltbio.com
About Bolt Biotherapeutics
Bolt Biotherapeutics was founded in 2015 by Dr. Edgar G. Engleman of Stanford University to expand upon his pioneering work in cancer immunotherapeutics and myeloid biology. Bolt is based in the San Francisco Bay area.
Bolt’s highly qualified management team includes experienced leaders in immuno-oncology drug discovery, development and commercialization. Our goal is to leverage our myeloid biology expertise to discover, develop and commercialize transformative treatments to address key unmet medical needs for patients with cancer.
70 articles with Bolt Biotherapeutics
-
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
3/14/2023
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with new preclinical data for BDC-3042, a Dectin-2-targeting agonistic antibody, at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2023.
-
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
2/28/2023
Bolt Biotherapeutics announced that management will present a company overview at the Cowen 43rd Annual Healthcare Conference on Tuesday, March 7, 2023, at 2:50 p.m. EST in Boston, Mass.
-
Bolt Biotherapeutics to Present at February 2023 Investor Conferences
2/1/2023
Bolt Biotherapeutics, a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, announced that management will participate in two upcoming conferences in February.
-
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
12/14/2022
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.
-
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
-
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/10/2022
Bolt Biotherapeutics, Inc. reported financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
11/7/2022
Bolt Biotherapeutics, Inc. today announced that it will be presenting a poster with new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting.
-
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
11/1/2022
Bolt Biotherapeutics announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, Nov. 16, 2022, at 1:15 p.m. EST in New York, New York.
-
Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
8/31/2022
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 12:20 p.m. ET (9:20 a.m. PT) in New York, New York.
-
In an effort to extend cash flow through 2025, Bolt Biotherapeutics announced it is shifting its priorities to focus on two immune-stimulating antibody conjugates (ISAC) programs.
-
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
8/10/2022
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
5/27/2022
Bolt Biotherapeutics, Inc. today announced that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022.
-
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/12/2022
Bolt Biotherapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business highlights.
-
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
4/7/2022
Bolt Biotherapeutics announced that management will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022, at 12:45 p.m. PT.
-
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
3/30/2022
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent business highlights.
-
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
-
Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022
3/8/2022
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it will present posters for three of the company’s preclinical pipeline programs at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2022.
-
That’s the advice for emerging growth life sciences companies in 2022, according to attorney Frank Rahmani, partner in the global life science and capital markets practice group at Sidley Austin LLP.
-
Bolt Biotherapeutics to Participate in Upcoming February 2022 Conferences
2/2/2022
Bolt Biotherapeutics announced that management will present at two upcoming conferences in February.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.